News
As the Trump administration begins to make its mark on the Medicare drug price negotiation program, litigation over the ...
Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and ...
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...
6d
Zacks Investment Research on MSNJNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise
Johnson & Johnson’s JNJ second-quarter 2025 earnings came in at $2.77 per share, which beat the Zacks Consensus Estimate of $2.66. Earnings, however, declined 1.8% from the year-ago period. Adjusted ...
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into RxSight, Inc. (NASDAQ: RXST) for potential violations of the federal securities laws. If you invested in RxSight, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results